WindMIL Therapeutics is an emerging biopharmaceutical company dedicated to the advancement of a novel class of cell therapy.  This therapy, licensed from the Johns Hopkins Sidney Kimmel Cancer Center and Drs. Ivan Borrello and Kimberly Noonan, has the potential to transform the treatment of cancer by providing cancer patients a re-activated and expanded population of autologous memory T cells that uniquely recognize the patient’s own tumor via the native TCR.  We call this therapy Re-activation of Anti-tumor Memory Immunotherapy (RAM Immunotherapy).

Contact WindMIL Therapeutics
Visit Website